Abstract
Purpose: Meningiomas are generally benign and in most cases surgery is curative. However, for high-grade histotypes or partially resected tumours, recurrence is fairly common. External beam radiation therapy (EBRT) is usually given in such cases but is not always effective. We assessed peptide receptor radionuclide therapy (PRRT) using 90Y-DOTATOC in a group of patients with meningioma recurring after standard treatments in all of whom somatostatin receptors were strongly expressed on meningioma cell surfaces. Methods: Twenty-nine patients with scintigraphically proven somatostatin subtype 2 receptor-positive meningiomas were enrolled: 14 had benign (grade I), 9 had atypical (grade II) and 6 had malignant (grade III) disease. Patients received intravenous 90Y-DOTATOC for 2-6 cycles for a cumulative dose in the range of 5-15 GBq. Clinical and neuroradiological evaluations were performed at baseline, during and after PRRT. Results: The treatment was well tolerated in all patients. MRI 3 months after treatment completion showed disease stabilization in 19 of 29 patients (66%) and progressive disease in the remaining 10 (34%). Better results were obtained in patients with grade I meningioma than in those with grade II-III, with median time to progression (from beginning PRRT) of 61 months in the low-grade group and 13 months in the high-grade group. Conclusion: PRRT with 90Y-DOTATOC can interfere with the growth of meningiomas. The adjuvant role of this treatment, soon after surgery, especially in atypical and malignant histotypes, deserves further investigation.
| Original language | English |
|---|---|
| Pages (from-to) | 1407-1416 |
| Number of pages | 10 |
| Journal | European Journal of Nuclear Medicine and Molecular Imaging |
| Volume | 36 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sep 2009 |
Fingerprint
Keywords
- Y-DOTATOC
- Meningioma
- Octreotide
- Peptide receptor radionuclide therapy
- Somatostatin receptor
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma. / Bartolomei, Mirco; Bodei, Lisa; De Cicco, Concetta; Grana, Chiara Maria; Cremonesi, Marta; Botteri, Edoardo; Baio, Silvia Melania; Aricò, Demetrio; Sansovini, Maddalena; Paganelli, Giovanni.
In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 36, No. 9, 09.2009, p. 1407-1416.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma
AU - Bartolomei, Mirco
AU - Bodei, Lisa
AU - De Cicco, Concetta
AU - Grana, Chiara Maria
AU - Cremonesi, Marta
AU - Botteri, Edoardo
AU - Baio, Silvia Melania
AU - Aricò, Demetrio
AU - Sansovini, Maddalena
AU - Paganelli, Giovanni
PY - 2009/9
Y1 - 2009/9
N2 - Purpose: Meningiomas are generally benign and in most cases surgery is curative. However, for high-grade histotypes or partially resected tumours, recurrence is fairly common. External beam radiation therapy (EBRT) is usually given in such cases but is not always effective. We assessed peptide receptor radionuclide therapy (PRRT) using 90Y-DOTATOC in a group of patients with meningioma recurring after standard treatments in all of whom somatostatin receptors were strongly expressed on meningioma cell surfaces. Methods: Twenty-nine patients with scintigraphically proven somatostatin subtype 2 receptor-positive meningiomas were enrolled: 14 had benign (grade I), 9 had atypical (grade II) and 6 had malignant (grade III) disease. Patients received intravenous 90Y-DOTATOC for 2-6 cycles for a cumulative dose in the range of 5-15 GBq. Clinical and neuroradiological evaluations were performed at baseline, during and after PRRT. Results: The treatment was well tolerated in all patients. MRI 3 months after treatment completion showed disease stabilization in 19 of 29 patients (66%) and progressive disease in the remaining 10 (34%). Better results were obtained in patients with grade I meningioma than in those with grade II-III, with median time to progression (from beginning PRRT) of 61 months in the low-grade group and 13 months in the high-grade group. Conclusion: PRRT with 90Y-DOTATOC can interfere with the growth of meningiomas. The adjuvant role of this treatment, soon after surgery, especially in atypical and malignant histotypes, deserves further investigation.
AB - Purpose: Meningiomas are generally benign and in most cases surgery is curative. However, for high-grade histotypes or partially resected tumours, recurrence is fairly common. External beam radiation therapy (EBRT) is usually given in such cases but is not always effective. We assessed peptide receptor radionuclide therapy (PRRT) using 90Y-DOTATOC in a group of patients with meningioma recurring after standard treatments in all of whom somatostatin receptors were strongly expressed on meningioma cell surfaces. Methods: Twenty-nine patients with scintigraphically proven somatostatin subtype 2 receptor-positive meningiomas were enrolled: 14 had benign (grade I), 9 had atypical (grade II) and 6 had malignant (grade III) disease. Patients received intravenous 90Y-DOTATOC for 2-6 cycles for a cumulative dose in the range of 5-15 GBq. Clinical and neuroradiological evaluations were performed at baseline, during and after PRRT. Results: The treatment was well tolerated in all patients. MRI 3 months after treatment completion showed disease stabilization in 19 of 29 patients (66%) and progressive disease in the remaining 10 (34%). Better results were obtained in patients with grade I meningioma than in those with grade II-III, with median time to progression (from beginning PRRT) of 61 months in the low-grade group and 13 months in the high-grade group. Conclusion: PRRT with 90Y-DOTATOC can interfere with the growth of meningiomas. The adjuvant role of this treatment, soon after surgery, especially in atypical and malignant histotypes, deserves further investigation.
KW - Y-DOTATOC
KW - Meningioma
KW - Octreotide
KW - Peptide receptor radionuclide therapy
KW - Somatostatin receptor
UR - http://www.scopus.com/inward/record.url?scp=68949212314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68949212314&partnerID=8YFLogxK
U2 - 10.1007/s00259-009-1115-z
DO - 10.1007/s00259-009-1115-z
M3 - Article
C2 - 19319527
AN - SCOPUS:68949212314
VL - 36
SP - 1407
EP - 1416
JO - European Journal of Pediatrics
JF - European Journal of Pediatrics
SN - 0340-6199
IS - 9
ER -